While several COVID-19 vaccines have been approved to date, the constant evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor-binding domain (RBD) has challenged the...

It is essential to face some grim facts about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen. The ongoing COVID-19 (coronavirus disease 2019) pandemic, started in December...

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based...

In a new study posted to the bioRxiv* preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe...

The coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread across the globe. The virus first emerged in Wuhan City, China,...

Researchers in the United States have conducted a study showing the efficacy of the Moderna and Pfizer-BioNTech vaccines at eliciting a robust T cell response against variants of severe acute respiratory...

UT Southwestern Medical Center scientists have identified the first cases of the Brazilian variant of COVID-19 infection in North Texas using next-generation sequencing technologies along with PCR testing. UT...

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model....

A new study, released on the bioRxiv* preprint server, shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host...

The lack of new or repurposed drugs to treat patients with severe or critical coronavirus disease 2019 (COVID-19) has been one of the biggest hurdles to reducing mortality rates in the ongoing pandemic...